bioRxiv · 18 Nov 2026
VINCIT: A virus-incorporated biomaterial niche enables spatially controlled in vivo CAR T cell engineering
K. D. Goodier, Y. Zhu, C. Wei, Z. Jiang, Y. Jiang, X. Lu, S. Chen, A. Greco, D. Yuh-index 2, X. Liu, J. Choy, Y. Su, J. Ma, J. Lin, J. Kong, E. Wang, D. Luong, D. S. Wilson, J. C. Doloff, J. Schneck, M. F. Konig, H.-Q. Mao
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
In vivo generation of chimeric antigen receptor (CAR) T cells could bypass the complex manufacturing required for conventional cell therapies, but systemic gene delivery remains limited by off target exposure and inefficient access to target immune cells. Here, we develop VINCIT (Virus Incorporated Niche for Cellular ImmunoTherapy), an injectable nanofiber hydrogel composite that establishes a localized immune-engineering niche for CAR T cell generation in vivo. VINCIT spatially retains viral vectors while recruiting endogenous immune cells, enabling local transduction of T cells, after which the engineered T cells enter the circulation. VINCIT spatially confines transgene expression compared with intravenous viral delivery and markedly enhances T cell transduction compared with subcutaneously injected free virus. VINCIT is compatible with both adeno-associated and lentiviral vectors, and CAR T cells generated in vivo exhibit antigen-specific effector responses and mediate CD19+ B cell depletion. In a humanized mouse model of lymphoma, a single VINCIT administration produces sustained tumor control and extends median survival from 32 to 110 days. Mechanistically, efficient CAR T cell generation requires coordinated interactions among multiple immune populations, with neutrophil depletion markedly reducing cellular recruitment and subsequent T cell programming. These findings establish a localized biomaterial niche for spatially controlled in vivo immune cell engineering.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- D. Yu has the highest h-index among the authors (2).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.